[go: up one dir, main page]

TW200726485A - Liposomal delivery vehicle for hydrophobic drugs - Google Patents

Liposomal delivery vehicle for hydrophobic drugs

Info

Publication number
TW200726485A
TW200726485A TW095123732A TW95123732A TW200726485A TW 200726485 A TW200726485 A TW 200726485A TW 095123732 A TW095123732 A TW 095123732A TW 95123732 A TW95123732 A TW 95123732A TW 200726485 A TW200726485 A TW 200726485A
Authority
TW
Taiwan
Prior art keywords
drug
delivery vehicle
hydrophobic drugs
liposomal delivery
concentration
Prior art date
Application number
TW095123732A
Other languages
English (en)
Inventor
Yuan-Peng Zhang
Bing Luo
Laxmi Iyer
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of TW200726485A publication Critical patent/TW200726485A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
TW095123732A 2005-07-01 2006-06-30 Liposomal delivery vehicle for hydrophobic drugs TW200726485A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69596105P 2005-07-01 2005-07-01

Publications (1)

Publication Number Publication Date
TW200726485A true TW200726485A (en) 2007-07-16

Family

ID=37605107

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095123732A TW200726485A (en) 2005-07-01 2006-06-30 Liposomal delivery vehicle for hydrophobic drugs

Country Status (3)

Country Link
US (1) US20070014845A1 (zh)
TW (1) TW200726485A (zh)
WO (1) WO2007005754A2 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794595B2 (en) * 2006-08-28 2010-09-14 Brian Charles Keller Method for encapsulation, remediation and recovery of spilled oil
US20090196917A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
WO2009149599A1 (zh) * 2008-06-11 2009-12-17 Liu Yanfang 脂质体药剂及其制备方法和用途
DK177529B1 (en) * 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
CN102596178B (zh) * 2009-10-26 2014-12-03 石药集团中奇制药技术（石家庄）有限公司 具有磺丁基醚环糊精盐内水相的脂质体
US11357728B2 (en) 2009-10-26 2022-06-14 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
EP2394640A1 (en) * 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
CN107261110A (zh) * 2010-06-19 2017-10-20 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
EP2468259A1 (en) * 2010-12-23 2012-06-27 Traslational Cancer Drugs Pharma, S.L. Pharmaceutical compositions of pyridinium and quinolinium derivatives
WO2012118376A1 (en) 2011-03-01 2012-09-07 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
EP3939572B1 (en) 2012-04-12 2024-03-27 Yale University Vehicles for controlled delivery of different pharmaceutical agents
WO2014054005A2 (es) * 2012-10-04 2014-04-10 Dajas Federico PREPARACIÓN NANOSOMAL DEL COMPLEJO FORMADO POR QUERCETINA (U OTRO FLAVONOL, FLAVONA O UN DERIVADO DE LOS MISMOS) Y LA 2-HYDROXIPROPIL- β-CICLODEXTRINA PARA USO INTRAVENOSO EN PATOLOGÍA CEREBRAL
US20140220110A1 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into liposomes
WO2014121235A2 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CN105848649B (zh) 2013-11-01 2019-08-02 耶鲁大学 用于免疫疗法的模块化粒子
EP3142642B1 (en) * 2014-04-10 2018-08-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Liposomal mupirocin
JP6263609B2 (ja) * 2014-04-30 2018-01-17 富士フイルム株式会社 リポソーム組成物及びその製造方法
EP3138558B1 (en) * 2014-04-30 2023-06-07 FUJIFILM Corporation Liposome composition and production method therefor
DK3138555T3 (da) 2014-04-30 2020-12-14 Fujifilm Corp Liposomsammensætning og fremgangsmåde til fremstilling heraf
US10004759B2 (en) 2014-08-04 2018-06-26 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
CN104306269B (zh) * 2014-11-04 2017-02-01 珀莱雅化妆品股份有限公司 一种具美白效果的环糊精包合物脂质体的制备方法
ES2869283T3 (es) 2015-11-02 2021-10-25 Fujifilm Corp Agente terapéutico antitumoral que contiene composición de liposoma de gemcitabina y kit
CN107260681A (zh) * 2017-08-04 2017-10-20 济南维瑞医药科技开发有限公司 一种磷酸特地唑胺脂质体的制备方法及其应用
WO2019133916A1 (en) * 2017-12-29 2019-07-04 Wayne State University Drug delivery systems for treatment of infections
JP7364561B2 (ja) 2018-06-20 2023-10-18 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
KR20240152302A (ko) * 2021-12-22 2024-10-21 아카제라 메디신즈, 인크. 옥사졸리디논 리포좀 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0261719A3 (en) * 1986-09-23 1990-10-10 Akzo N.V. Thermochemiluminescent cyclodextrin complexes
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
DE4010355A1 (de) * 1990-03-28 1991-10-02 Schering Ag Bicyclo(3.3.0)octan-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
AU6818094A (en) * 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5464629A (en) * 1993-11-16 1995-11-07 Georgetown University Method of forming hydrogel particles having a controlled size using liposomes
GB9411115D0 (en) * 1994-06-03 1994-07-27 Secr Defence Stabilisation of photosensitive material
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP0932390A1 (en) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6224903B1 (en) * 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
RU2250911C2 (ru) * 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
WO2003008389A1 (en) * 2001-07-16 2003-01-30 Ranbaxy Laboratories Limited Oxazolidinone derivatives as potential antimicrobials
AUPR272901A0 (en) * 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
JP2004525138A (ja) * 2001-03-26 2004-08-19 アルザ・コーポレーシヨン 治療剤の改良された細胞内送達のためのリポソーム組成物
AU2002258913A1 (en) * 2001-04-23 2002-11-05 Wisconsin Alumni Research Foundation Bifunctional-modified hydrogels
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues

Also Published As

Publication number Publication date
WO2007005754A2 (en) 2007-01-11
US20070014845A1 (en) 2007-01-18
WO2007005754A3 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
TW200726485A (en) Liposomal delivery vehicle for hydrophobic drugs
Cosco et al. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases
Nakamura et al. Comparative studies of polyethylene glycol-modified liposomes prepared using different PEG-modification methods
Zheng et al. Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease: Zheng et al.
Alavi et al. Utilization of chitosan-caged liposomes to push the boundaries of therapeutic delivery
Chen et al. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats
Huang et al. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin
DK2879502T3 (en) COCHLEATES PREPARED WITH SOYAPHOSPHATIDYLSERINE
WO2005054279A8 (en) Delivery peptides, their constructs with active agents and use
WO2013008240A8 (en) Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
TW200600095A (en) Irinotecan formulation
Shigehiro et al. Efficient drug delivery of paclitaxel glycoside: A novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparation
CN106466299A (zh) 以人参皂苷为膜材的空白脂质体、其制备方法及应用
Lila et al. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor
WO2008140081A1 (ja) リポソームおよびリポソームの製造方法
WO2008109031A3 (en) Liposome carriers for in vivo delivery of fullerenes
WO2008042973A3 (en) Lipid containing formulations
WO2012031175A8 (en) Nanoparticle-based tumor-targeted drug delivery
EP1874793A4 (en) DISTRIBUTION OF SIRNA BY NEUTRAL LIPID COMPOSITIONS
Lin et al. Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer
Yang et al. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells
WO2005094783A3 (de) Serumstabile amphotere liposomen
Su et al. Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance
Li et al. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy
Ying et al. Delivery of kinesin spindle protein targeting siRNA in solid lipid nanoparticles to cellular models of tumor vasculature